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Dear Editor,
In the editorial from Maina and Di Napoli [1], the important issue concerning the number of authors 
of a review was considered in its essential aspects. The authors stated that, in order «to avoid the un-
controlled proliferation of authors and co-authors», Reviews in Health Care decided to fix a maximum 
of 10 authors for each article.
In this contribution we would like to underline another issue: how to report a review?
The need of specific reporting guidelines for medical journals is beyond dispute. With that regard a 
number of statements were developed by groups of experts to facilitate reporting of research studies. 
Most medical journals, including British Medical Journal (BMJ), the Journal of the American Medical 
Association (JAMA), The Lancet, and New England Journal of Medicine, often require compliance to all 
or some of the following guidelines: CONSORT Statement (reporting of randomized controlled trials), 
STARD (reporting of diagnostic accuracy studies), STROBE (reporting of observational studies in epi-
demiology), PRISMA (reporting of systematic reviews and meta-analyses) and MOOSE (reporting of 
meta-analyses of observational studies). 
The present letter concerns the standards of reporting in research, publication in medical journals 
and wishes to give an emphasis to the PRISMA (Preferred Reporting Items for Systematic reviews and 
Meta-Analyses) statement. 
There is no doubt that, according to the PRISMA statement [2], the number of authors for a systematic 
review needs to be at least 2 (“Eligibility assessment to be performed independently in an unblended 
standardized manner by 2 reviewers”).
PRISMA is an evidence-based set of 27-item checklist (Table I) and a four-phase flow diagram (Figure 
1) and it’s basically an expansion of the QUOROM Statement developed in 1996 (QUality Of Reporting 
Of Meta-analyses). 
The Statement was developed by a group of 29 review authors, methodologists, clinicians, medical 
editors, and consumers [3]. The flow diagram originally proposed by QUOROM was modified to show 
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numbers of identified records, excluded articles, and included studies. Items considered essential for 
transparent reporting of a systematic review were also included in the checklist. After 11 revisions the 
group approved the checklist and the flow diagram. The items are presented numerically from 1-27, but 
it is not necessary to address them in that particular order in a report. Fundamentally, what is impor-
tant is that the information for each item is given somewhere within the report [2].
Section/topic Item No Checklist item
Reported 
on page No
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both
Abstract
Structured 
summary
2 Provide a structured summary including, as applicable: background; objectives; 
data sources; study eligibility criteria, participants, and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and implications 
of key findings; systematic review registration number 
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known
Objectives 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS) 
Methods
Protocol and 
registration
5 Indicate if a review protocol exists, if and where it can be accessed (eg web address), 
and, if available, provide registration information including registration number 
Eligibility 
criteria
6 Specify study characteristics (eg PICOS, length of follow-up) and report 
characteristics (eg years considered, language, publication status) used as criteria 
for eligibility, giving rationale 
Information 
sources
7 Describe all information sources (eg databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched 
Search 8 Present full electronic search strategy for at least one database, including any 
limits used, such that it could be repeated
Study 
selection
9 State the process for selecting studies (ie, screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis)
Data 
collection 
process
10 Describe method of data extraction from reports (eg piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming data 
from investigators 
Data items 11 List and define all variables for which data were sought (eg PICOS, funding 
sources) and any assumptions and simplifications made 
Risk of bias 
in individual 
studies
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how 
this information is to be used in any data synthesis 
Summary 
measures
13 State the principal summary measures (such as risk ratio, difference in means)
Synthesis of 
results
14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (eg I2 statistic) for each meta-analysis
Risk of bias 
across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (eg 
publication bias, selective reporting within studies) 
Additional 
analyses
16 Describe methods of additional analyses (eg sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified
Results
Study 
selection
17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram 
Table continues >
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Section/topic Item No Checklist item
Reported 
on page No
Study 
characteristics
18 For each study, present characteristics for which data were extracted (eg study 
size, PICOS, follow-up period) and provide the citations 
Risk of bias 
within studies
19 Present data on risk of bias of each study and, if available, any outcome-level 
assessment (see item 12)
Results of 
individual 
studies
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group and (b) effect estimates and 
confidence intervals, ideally with a forest plot 
Synthesis of 
results
21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency
Risk of bias 
across studies
22 Present results of any assessment of risk of bias across studies (see item 15)
Additional 
analysis
23 Give results of additional analyses, if done (such as sensitivity or subgroup 
analyses, meta-regression) (see item 16)
Discussion
Summary of 
evidence
24 Summarise the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (eg health care providers, users, 
and policy makers) 
Limitations 25 Discuss limitations at study and outcome level (eg risk of bias), and at review level 
(eg incomplete retrieval of identified research, reporting bias) 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, 
and implications for future research
Funding
Funding 27 Describe sources of funding for the systematic review and other support (eg 
supply of data); role of funders for the systematic review 
Table I. Checklist of items to include when reporting a systematic review (with or without meta 
analysis) [2]
Figure 1. Flow of information through the different phases of a systematic review
> Table continued
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Systematic reviews (SRs) and meta-analyses are essential tools for summarising evidence accurately 
and reliably. They help clinicians keep up-to-date; provide evidence for policy makers to judge risks, 
benefits, and harms of health care behaviours and interventions; gather together and summarise related 
research for patients and their carers; provide a starting point for clinical practice guideline developers; 
provide summaries of previous research for funders wishing to support new research [4]; and help 
editors judge the merits of publishing reports of new studies [5]. 
Poor reporting of key information is often in SRs and that diminishes their potential usefulness [6]; 
therefore, PRISMA focuses on ways in which authors can ensure the transparent and complete repor-
ting of their researches. It does not address directly or in a detailed manner the conduct of SRs, for 
which other guides are available [7,8]. 
Several research and publication ethics standards have been set up. These include the Nuremberg Code, 
the Declaration of Helsinki, the International Committee of Medical Journal Editors (ICMJE) Uniform 
Requirements for Manuscripts to Biomedical Journals, recommendations of the World Association of 
Medical Editors and the Committee on Publication Ethics [9]. 
The study carried out in 2010 by Pitak-Arnnop revealed the lack of disclosures of human subject 
protection (obtaining ethical approval and subject’s consent), financial conflicts, and academic-in-
dustry relationship in oral-maxillofacial surgery (OMS) journals and innovations. Funding sources 
were disclosed in only 26.4% of controlled trials published in OMS journals. Their recent studies 
demonstrated that 9 of 29 clinical studies (31%) on piezoelectric OMS procedures were dual or frag-
mented publications in journals of different disciplines or different languages and that OMS authors 
had a considerably different understanding of research ethics. Multiple factors may contribute to such 
scientific misconduct. These include inadequate research experience, bias from career self-interest or 
financial gains, lack of knowledge about research and publication ethics, or a combination of these 
[9]. Moreover, guidelines for authors are usually limited and inconsistent among different journals 
[10,11]. 
Other factors could lead to a bias in evidence, for instance unpublished grey literature or publications 
in non-electronic journals are difficult to identify and are often not detected in systematic searches. 
Even though a study is published in electronic journals not every journal is listed on the major data-
bases like PubMed.gov or Embase which hinders its identification. Most of the published studies are 
not accessible openly and in addition many large clinical centres do not have all the necessary licenses 
for all the relevant publications which limit the number of studies they can identify [12]. Therefore, 
knowing that publication bias is always present it’s advisable to take it into account when reading meta-
analyses and systematic reviews.
Publication bias occurs when «investigators, reviewers, and editors submit or accept manuscripts for 
publication based on the direction or strength of the study findings» [13]. The ICMJE underlines that 
negative studies should be published: «Editors should seriously consider for publication any carefully 
done study of an important question, relevant to their readers, whether the results for the primary or 
any additional outcome are statistically significant. Failure to submit or publish findings because of lack 
of statistical significance is an important cause of publication bias».
The impact of publication bias has been widely examined for clinical trials [14-16], for which it has 
been suggested that studies with statistically positive results and large effect sizes can exaggerate a tre-
atment’s effectiveness by 20% [17]. 
The PRISMA Statement calls for an international registry for SR protocols [18], which is under deve-
lopment [19]. An international registry may decrease the number of unpublished SRs and will hopeful-
ly decrease redundancy, increase transparency and collaboration within the SR community.
The interpretation of SR results may be improved by using the PRISMA Statement and GRADE (Gra-
ding of Recommendations Assessment, Development, and Evaluation) which considers four factors 
in grading the strength of recommendations: quality, benefit versus harm, values, preferences and re-
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sources [20,21]. A categorisation guide for meta-analysis results would be also useful. Such efforts will 
increase the applicability and relevance of the SR findings and may help to ensure adequate interpre-
tation of the results.
The purpose of this letter is to encourage health care journals and editorial groups, such as the World 
Association of Medical Editors and the International Committee of Medical Journal Editors, to endorse 
PRISMA in much the same way as they have endorsed other reporting guidelines, such as CONSORT. 
We also encourage editors of health care journals to support PRISMA by updating their ‘‘Instructions 
to Authors’’ and including the PRISMA Web address, and by raising awareness through specific edi-
torial actions.
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